• Menu
• » Administrative Rules Related
• » Statements of Scope
• » Active Scope Statements

Controlled Substances Board (CSB) Stop grouping [View All]

• SS 088-24

  CR 24-085

  2/5/2027

  Relating to: Scheduling 2-methyl AP–237
• SS 087-24

  CR 24-084

  2/5/2027

  Relating to: Scheduling ADB-BUTINACA, a-PiHP, and 3-MMC
• SS 086-24

  CR 24-083

  2/5/2027

  Relating to: Scheduling 5 synthetic cannabinoids
• SS 049-24

  CR 24-059

  11/13/2026

  Relating to: Scheduling nine fentanyl-related substances
• SS 048-24

  CR 24-058

  11/13/2026

  Relating to: Scheduling zuranolone
• SS 022-24

  CR 24-060

  8/12/2026

  Relating to: Mail delivered prescriptions
• SS 001-24

  CR 24-048

  7/2/2026

  Relating to: Transferring flualprazolam and scheduling 4 other synthetic benzodiazepine substances
• SS 079-23

  CR 24-024

  4/23/2026

  Relating to: Excluding fenfluramine
• SS 078-23

  CR 24-023

  4/23/2026

  Relating to: Scheduling methiopropamine
• SS 055-23

  CR 24-033

  2/7/2026

  Relating to: Monitored prescription drug history reports
• SS 054-23

  CR 24-005

  2/7/2026

  Relating to: Scheduling Mesocarb
• SS 053-23

  CR 24-004

  2/7/2026

  Relating to: Excluding [18F]FP-CIT
• SS 052-23

  CR 23-069

  2/7/2026

  Relating to: Scheduling Zipeprol
• SS 051-23

  CR 23-068

  2/7/2026

  Relating to: Scheduling Amineptine
• SS 095-22

  CR 24-013

  5/21/2025

  Relating to: National provider identifier requirement
• SS 094-22

  CR 23-021

  5/21/2025

  Relating to: Scheduling Ganaxolone
• SS 093-22

  CR 23-020

  5/21/2025

  Relating to: Scheduling seven (7) synthetic benzimidazole-opioid substances
• SS 092-22

  CR 23-019

  5/21/2025

  Relating to: Scheduling Daridorexant
• SS 091-22

  CR 23-018

  5/21/2025

  Relating to: Scheduling thirty-eight (38) anabolic steroids